In part 4 and the conclusion of this Exclusive Interview about the new diabetes classification, Dr. Schwartz highlights what he is looking forward to at the AACE and ADA conferences, particularly the results of the LEADER and GLP-1 studies.
Read More »
In Part 2 of this exclusive interview, Dr. Robert Geho discusses the Phase 2b study which focuses on adding Diasome's HDV to a leading pre-meal fast acting analogue.
Read More »
In part one of this exclusive interview, Dr. Robert Geho discusses the essential role of the liver in metabolizing insulin, and asks why we hear about the artificial pancreas all the time, but never hear anyone talk about an artificial liver?
Read More »In this Exclusive Interview, Dr. Robert Geho joins Diabetes in Control publisher Steve Freed at the 2016 Diabetes Symposium in Boston to discuss the testing, affects, and potential marketing of a new insulin delivery system currently undergoing trials. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. …
Read More »
In Part 7, the final installment of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the potential marketing and timing of the product offering. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. In his role at Diasome, he leads the …
Read More »
In Part 6 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho and Diabetes in Control publisher Steve Freed discuss the possible reduction in the use of insulin as well as hypoglycemia following the use of the product. Robert Geho, MD, is a co-founder and CEO …
Read More »
In Part 5 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the potential effect of the proper storage of insulin within the liver on the overall weight of the patient. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. In …
Read More »
In Part 4 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, understanding the best insulin for the admixture and the possible effect on A1C. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. In his role at Diasome, he leads the management and strategic …
Read More »
In Part 3 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the focus on the phase of trials. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. In his role at Diasome, he leads the management and strategic direction of …
Read More »
In Part 2 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the effect of insulin on the liver. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. In his role at Diasome, he leads the management and strategic direction of …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.